Loading…
Ascentage Pharma Group Internat is projected to rise to $26.37 by 2027, a +26% move from its current price of $20.90. AAPG is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $20.25 | $20.90 | $21.57 | -0.02% |
| May 30 | $19.98 | $20.89 | $21.85 | -0.03% |
| May 31 | $19.78 | $20.89 | $22.07 | -0.05% |
| Jun 1 | $19.61 | $20.89 | $22.25 | -0.07% |
| Jun 2 | $19.46 | $20.88 | $22.41 | -0.08% |
| Jun 3 | $19.32 | $20.88 | $22.56 | -0.10% |
| Jun 4 | $19.20 | $20.88 | $22.70 | -0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.20 | $20.88 | $22.70 | -0.12% |
| Week 2 | $18.52 | $20.85 | $23.47 | -0.24% |
| Week 3 | $18.02 | $20.83 | $24.08 | -0.35% |
| Week 4 | $17.60 | $20.80 | $24.59 | -0.47% |
| Week 5 | $17.23 | $20.78 | $25.05 | -0.59% |
| Week 6 | $16.91 | $20.75 | $25.48 | -0.70% |
| Week 7 | $16.61 | $20.73 | $25.87 | -0.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ascentage Pharma Group International is a clinical-stage biotechnology company that develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
Its primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, APG-115, APG-1252, APG-1387, and APG-5918.
In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Ascentage Pharma Group Internat (AAPG) is currently trading with a price of $21.01 per share and a market capitalization of $1.96B, holding a market rank of 2017.
The price outlook is shown by a year-by-year forecast that starts in 2026 with an average price near the current level and then trends higher in subsequent years, with a max price reaching $54.33 in 2030 and a max price reaching $299.71 in 2050.
Forecasted averages rise from $21.01 in 2026 to $26.38 in 2027, $33.29 in 2028, $36.04 in 2029, $35.43 in 2030, $37.99 in 2031, $37.54 in 2032, $42.41 in 2033, $53.65 in 2034, $56.18 in 2035, $71.02 in 2040, and $148.16 in 2050, with corresponding max values culminating at $299.71 in 2050.
The outlook overall shows bullish sentiment from 2027 onward, with notable gains implied by the max forecasts and ROI figures, though forecasts are estimates and not guarantees.
A major floor 35.7% below — a decisive break under it would weaken the trend.
The nearest floor, 11.2% below — buyers have tended to step in here.
The nearest ceiling, 31.1% above — a clean break opens room to run.
A major ceiling 48.9% above — clearing it would confirm fresh momentum.
Key AAPG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AAPG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.50 | Buy | $20.47 | Buy |
| MA 10 | $20.11 | Buy | $20.52 | Buy |
| MA 20 | $21.06 | Sell | $21.19 | Sell |
| MA 50 | $23.16 | Sell | $22.70 | Sell |
| MA 100 | $24.10 | Sell | $24.56 | Sell |
| MA 200 | $29.91 | Sell | $26.53 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.70 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -11.11 | Neutral |
| Williams %R (14) | -25.48 | Info |
| MACD (12,26,9) | 0.11 | Buy |
| ROC (12) | -2.79 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 74.52 | Neutral |
| TRIX (15) | -0.70 | Sell |
| Awesome (5,34) | -2.30 | Sell |
| Ultimate (7,14,28) | 54.42 | Neutral |
| Momentum (10) | -0.26 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 21.00 | Sell |
| ADX (14) | 21.20 | Sell |
| ATR (14) | 0.66 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 50.
Key moving averages show SMA50 at $23.32 and SMA200 at $30.13, with near-term dynamics balanced between gains and headwinds.
Support is listed at $18.56 and resistance at $27.40, and the 30-day range spans from $17.08 to $25.84. Annualized volatility is around 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.56 | $20.90 | $31.28 | 0% | Neutral | |
| $20.40 | $26.37 | $36.40 | +26% | Bullish | |
| $24.68 | $33.04 | $47.62 | +58% | Bullish | |
| $26.13 | $36.04 | $53.73 | +72% | Bullish | |
| $25.13 | $35.58 | $54.58 | +70% | Bullish | |
| $26.08 | $37.83 | $59.49 | +81% | Bullish | |
| $25.34 | $37.60 | $60.47 | +80% | Bullish | |
| $28.02 | $42.48 | $69.71 | +103% | Bullish | |
| $34.55 | $53.46 | $89.37 | +156% | Bullish | |
| $35.89 | $56.65 | $96.34 | +171% | Bullish | |
| $40.83 | $70.59 | $128.95 | +238% | Bullish | |
| $73.66 | $149.89 | $303.57 | +617% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $18.56 | $20.90 | $24.52 | +0.00% |
| June 2026 | $17.04 | $20.12 | $24.41 | -3.73% |
| July 2026 | $17.24 | $20.58 | $25.39 | +2.29% |
| August 2026 | $18.12 | $21.81 | $27.25 | +5.96% |
| September 2026 | $18.20 | $22.05 | $27.83 | +1.10% |
| October 2026 | $18.23 | $22.23 | $28.32 | +0.80% |
| November 2026 | $19.11 | $23.44 | $30.11 | +5.46% |
| December 2026 | $19.60 | $24.16 | $31.28 | +3.08% |
Click any year to see its month-by-month AAPG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AAPG could reach as high as $31.28, with a base case around $20.90 and support toward $18.56 — roughly 0% from $20.90. Price action looks broadly range-bound.
Expect AAPG to range from $20.40 to $36.40 through 2027. The $26.37 average target implies a +26% move from current prices. That is up +26% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The AAPG price prediction for 2028 points to an average of $33.04 (low $24.68, high $47.62) — a potential gain of +58% on today's $20.90. Momentum favours further upside here.
In 2029, AAPG is projected to trade between $26.13 and $53.73, averaging $36.04 — a potential gain of +72% from today's $20.90. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Ascentage Pharma Group Internat's 2030 outlook centres on $35.58, within a $25.13 to $54.58 range. That is -1% versus the projected 2029 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2031, AAPG could reach as high as $59.49, with a base case around $37.83 and support toward $26.08 — roughly +81% from $20.90. Buyers look set to stay in control over this stretch.
Expect AAPG to range from $25.34 to $60.47 through 2032. The $37.60 average target implies a +80% move from current prices. That is -1% versus the projected 2031 average. Momentum favours further upside here.
The AAPG price prediction for 2033 points to an average of $42.48 (low $28.02, high $69.71) — a potential gain of +103% on today's $20.90. Buyers look set to stay in control over this stretch.
In 2034, AAPG is projected to trade between $34.55 and $89.37, averaging $53.46 — a potential gain of +156% from today's $20.90. That is up +26% on the projected 2033 average. Momentum favours further upside here.
Ascentage Pharma Group Internat's 2035 outlook centres on $56.65, within a $35.89 to $96.34 range. That is up +6% on the projected 2034 average. That marks a +171% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AAPG could reach as high as $128.95, with a base case around $70.59 and support toward $40.83 — roughly +238% from $20.90. Momentum favours further upside here.
Expect AAPG to range from $73.66 to $303.57 through 2050. The $149.89 average target implies a +617% move from current prices. That is up +112% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AAPG today (≈ 47.84689 AAPG) could be worth
$7,171.71
+$6,171.71 (+617%) by 2050 · US Dollar
Based on the average projected AAPG price of $149.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AAPGwould be worth at today's price.
$1,000 invested in AAPG on May 27, 2025 (≈ 38.737168 AAPG) would be worth
$809.61
-$190.39 (-19.0%) today · 0.81× · US Dollar
Based on a AAPG entry price of $25.82 vs. today's $20.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.78 | $1,056.62 | +5.7% |
| 1 month ago | $23.37 | $894.31 | -10.6% |
| 3 months ago | $24.1 | $867.22 | -13.3% |
| 6 months ago | $32.5 | $643.08 | -35.7% |
| 1 year ago | $25.82 | $809.61 | -19.0% |
| All time (1.3y) ago | $17.38 | $1,202.53 | +20.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AAPG forecast.
Our base-case forecast reaches $42.00 around 2033.
Implied market cap at $42.00: $3.92B
The multi-year forecast points to a bullish trajectory, with the average price rising from $26.38 in 2027 to $148.16 by 2050, and the 2030 average at $35.43. The forecast also shows high max values throughout the period, culminating in a 2050 max of $299.71 and a 2050 ROI of 605.2%. The path from 2027 onward is described as BULLISH, with growing average prices and positive ROIs across the years (e.g., 2027 avg $26.38, ROI 25.6%; 2040 avg $71.02, ROI 238%).
By 2040 the max price is forecast at $129.61, and by 2050 the max reaches $299.71.
Milestones include 2030 with an average of $35.43 and 68.6% ROI, 2040 with an average of $71.02 and 238% ROI, and 2050 with an average of $148.16 and 605.2% ROI. These figures illustrate a sustained bullish expectation over the long term, recognizing that actual results may differ from forecasts and that estimates carry uncertainty.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $35.43, with a min of $25.04 and a max of $54.33; ROI 68.6%; sentiment BULLISH.
The year-by-year forecast shows BULLISH sentiment from 2027 onward with rising average prices and positive ROIs in each year through 2050 (e.g., 2027 avg $26.38, ROI 25.6%; 2050 avg $148.16, ROI 605.2%). 2026 is neutral with ROI 0.
The forecast max reaches $129.61 in 2040 and $299.71 in 2050, so reaching $100 is projected within the horizon, with higher potential in the later years.
Current price is $21.01; market cap is $1.96B.
Sentiment is NEUTRAL; RSI14 is 50. The SMA50 is $23.32 and the SMA200 is $30.13, with support at $18.56 and resistance at $27.40. The 30-day range is $17.08 to $25.84, and annualized volatility is 60%.
Ascentage Pharma Group Internat Community Discussion
0Share your Ascentage Pharma Group Internat price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.